Search the Newsreel

Abbott Laboratories (ABT) Just Gave Investors Something To Think About

Abbott Laboratories (ABT) recently exceeded quarterly estimates and increased its annual profit forecast, driven by strong performance in cancer diagnostics and medical devices. The company's stock has shown a significant short-term rebound, up 28.77% over 90 days, despite being down over the past year. …

Carolina Wealth Advisors LLC Purchases 7,626 Shares of AbbVie Inc. $ABBV

Carolina Wealth Advisors LLC increased its stake in AbbVie Inc. by 68.6% in the second quarter, purchasing an additional 7,626 shares and bringing its total holdings to 18,741 shares valued at $4.716 million. Other institutional investors have also adjusted their positions in AbbVie, with …

Pharma giants, including AbbVie, sue to block Illinois drug discount law

Major pharmaceutical companies, including AbbVie, Bristol Myers, and Novartis, have filed a lawsuit to block a new drug discount law in Illinois. The lawsuit challenges the state's 340B law, which aims to provide discounted prescription drugs. This legal action by the pharma giants indicates …

Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped …

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie's Botox Cosmetic has moved closer to FDA approval for a fifth aesthetic use: treating masseter muscle prominence. This potential approval is based on positive Phase 3 study results and aligns with AbbVie's strategy of expanding existing drug indications. While the company shows strong …

AbbVie, Novartis Sue Illinois Over Hospital Drug Pharmacy Law

AbbVie and Novartis AG have filed separate lawsuits against the state of Illinois, challenging a new law that regulates drugmakers' contractual agreements with pharmacies under a federal drug discount program. AbbVie claims the law violates its constitutional property rights by mandating the transfer of …

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

Abbott Continues to Oppose Spinal Cord Stimulator Lawsuit MDL, Despite Mounting Claims

Abbott Laboratories is opposing the consolidation of spinal cord stimulator lawsuits into a multidistrict litigation (MDL), despite a growing number of claims alleging dangerous defects in its devices. While a similar MDL has already been established for Boston Scientific, Abbott argues that its cases …

AbbVie Stock After the Apogee Financing: What $10 Billion in Notes Signals.

AbbVie recently issued $10 billion in senior notes to finance its $10.9 billion acquisition of Apogee Therapeutics, with the deal expected to close on August 18. Despite narrowing full-year guidance due to acquisition-related dilution, AbbVie reported strong Q2 earnings driven by Skyrizi and Rinvoq …

AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results

AbbVie plans to acquire Apogee Therapeutics for $10.9 billion, or $135.11 per share, to bolster its immunology portfolio. This acquisition follows Apogee's positive Phase 2 results for zumilokibart in atopic dermatitis and a $1.3 billion financing deal with Blackstone Life Sciences. The deal is …

Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75

Apogee Therapeutics announced its Q2 2026 financial results and significant corporate updates, including AbbVie's agreement to acquire the company for approximately $10.9 billion. The acquisition, valued at $135.11 per share in cash, is expected to close in Q3 2026. Additionally, Apogee reported positive Phase …

Fluent Financial LLC Makes New $1.73 Million Investment in Abbott Laboratories $ABT

Vertrix Wealth Management LLC Invests $2.67 Million in Abbott Laboratories $ABT

Vertrix Wealth Management LLC initiated a new position in Abbott Laboratories (NYSE:ABT) during the second quarter, purchasing 29,377 shares valued at approximately $2.67 million. Institutional investors collectively own about 75.18% of the company. Abbott Laboratories reported strong quarterly earnings and revenue, beating estimates, and …

AbbVie Inc. (ABBV) Stock Analysis: Evaluating Growth Potential With A 11.51% Upside

AbbVie Inc. (ABBV) is a biopharmaceutical company with a strong market presence, a current stock price of $246.04, and a potential upside of 11.51% according to analyst ratings. While the company boasts significant revenue growth, strong operational efficiency, and an attractive dividend yield, its …

Abbott Laboratories (ABT) Stock Analysis: Exploring a 9.84% Potential Upside Amid Strong Revenue Growth

AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Brokerages

AbbVie Inc. (NYSE:ABBV) has received a "Moderate Buy" consensus rating from 24 brokerages, with an average 12-month price target of $275.70, exceeding its current share price. The company surpassed quarterly earnings expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, marking a …

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

Abbott Laboratories Aktie: 410. Quartalsdividende am 17. August

Gradient Investments LLC Sells 126,411 Shares of Abbott Laboratories $ABT

Gradient Investments LLC reduced its stake in Abbott Laboratories (ABT) by 34.9% in Q2 2026, selling over 126,000 shares but still retaining a significant holding worth $21.4 million. Despite this sale, institutional investors collectively own 75.18% of ABT. The company recently exceeded quarterly earnings …

Cabbeen Fashion (SEHK:2030) Stock Premium Rests On A One Off Profit Lift

AbbVie Inc (ABBV) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update

Abbott Laboratories (ABT) has completed a $1.35 billion share buyback, repurchasing over 14 million shares. Despite recent short-term gains, the company's shares are considered 9.5% undervalued, with a fair value estimated at $119.13 compared to its current price of $107.81. Growth drivers include expanding …

Análise e Previsão das Ações da AbbVie Inc (ABBV)

Análise e Previsão das Ações da Abbott Laboratories (ABT)

St. Louis Financial Planners Asset Management LLC Takes $5.01 Million Position in AbbVie Inc. $ABBV

St. Louis Financial Planners Asset Management LLC has acquired a new position in AbbVie Inc., purchasing 19,202 shares valued at approximately $5.01 million, making AbbVie its seventh-largest holding. This comes as AbbVie reported strong Q2 earnings, exceeding revenue and EPS expectations, though its adjusted …

Avior Wealth Management LLC Lowers Stake in Abbott Laboratories $ABT

Avior Wealth Management LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 47.5% in the second quarter, selling 19,199 shares and retaining 21,257 shares valued at $1.93 million. Despite this, analysts maintain a "Moderate Buy" rating for Abbott with an average price target of …

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a high-yield pharmaceutical powerhouse and a diversified healthcare leader requires looking at growth and stability. You must decide whether AbbVie (NYSE:ABBV) or Abbott Laboratories (NYSE:ABT) better fits your 2026 investment strategy. AbbVie focuses on high-margin specialized drugs, while Abbott operates across medical …

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

How Abbott Laboratories (ABT) Affects Rotational Strategy Timing

This article analyzes Abbott Laboratories (ABT) through the lens of rotational strategy timing, utilizing AI models to generate trading strategies. It highlights mixed sentiment, no clear price positioning signal, and compelling upside potential due to the absence of resistance levels above the current price. …

Cabbeen Fashion Declares HK$0.014 Mid-Year Dividend as 2026 Interim Results Signal Steady Discipline

Cabbeen Fashion Limited Reports Earnings Results for the Half Year Ended June 30, 2026

51,393 Shares in Abbott Laboratories $ABT Purchased by St. Louis Financial Planners Asset Management LLC

St. Louis Financial Planners Asset Management LLC recently acquired 51,393 shares of Abbott Laboratories (NYSE:ABT) worth approximately $4.9 million, making it their 10th-largest holding. Institutional investors now own 75.18% of the company, which holds a "Moderate Buy" consensus rating from analysts despite some recent …

What Makes Abbott Laboratories (ABT) a Compelling Investment Opportunity with Reliable Growth

Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors …

Abbott (ABT) Stock Trades At A Cash Flow Discount But An Earnings Premium

Abbott Laboratories' stock has dropped 16.4% over the past year, but a Discounted Cash Flow (DCF) analysis suggests a 28.1% upside compared to its current share price, indicating it's undervalued based on future cash flow potential. However, its P/E ratio of 34.6x is higher …

Projeções de Resultados: AbbVie Inc (ABBV) — LPA e Crescimento de Receita

ABB India Consolidated June 2026 Net Sales at Rs 3,558.87 crore, up 7.04% Y-o-Y